The Warfarin/Aspirin Study in Heart failure
ISRCTN | ISRCTN76146656 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN76146656 |
Secondary identifying numbers | D15 |
- Submission date
- 23/01/2004
- Registration date
- 23/01/2004
- Last edited
- 22/02/2008
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Circulatory System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Not provided at time of registration
Contact information
Prof John Cleland
Scientific
Scientific
Castle Hill Hospital
University of Hull
Cottingham
Kingston upon Hull
HU16 5UQ
United Kingdom
Phone | +44 (0)1482 624 083/084 |
---|---|
J.G.Cleland@hull.ac.uk |
Study information
Study design | Randomised controlled trial |
---|---|
Primary study design | Interventional |
Secondary study design | Randomised controlled trial |
Study setting(s) | Hospital |
Study type | Treatment |
Scientific title | What is the most cost effective anti-thrombotic strategy to reduce mortality in heart failure? The WASH Study |
Study acronym | WASH Study |
Study objectives | Heart failure is common and causes appreciable morbidity and mortality. It is associated with recurrent myocardial infarcts, strokes, and other thrombo-embolic events. For these reasons anti-thrombotic therapy using aspirin or warfarin is seen as normal clinical practice. However aspirin has a number of side-effects, and warfarin requires regular blood tests, increasing its cost and inconvenience for patients. Thus using these agents should be justified by clinical benefit. The aim of this study was to see if it would be possible to organise a trial of aspirin, warfarin, and no anti-thrombotic treatment. |
Ethics approval(s) | Not provided at time of registration |
Health condition(s) or problem(s) studied | Heart disease |
Intervention | 1. Aspirin 2. Wafarin 3. No anti-thrombotic treatment |
Intervention type | Other |
Primary outcome measure | 1. Deaths 2. Myocardial infarction 3. Stroke 4. Bleeding episodes 5. Dyspepsia 6. A number of laboratory tests |
Secondary outcome measures | Not provided at time of registration |
Overall study start date | 01/11/1995 |
Completion date | 30/09/1998 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Not Specified |
Sex | Not Specified |
Target number of participants | 279 |
Key inclusion criteria | Patients were being treated for heart failure, and had evidence of ventricular dysfunction to a defined level on echocardiography. |
Key exclusion criteria | Not provided at time of registration |
Date of first enrolment | 01/11/1995 |
Date of final enrolment | 30/09/1998 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
Castle Hill Hospital
Kingston upon Hull
HU16 5UQ
United Kingdom
HU16 5UQ
United Kingdom
Sponsor information
Record Provided by the NHS R&D 'Time-Limited' National Programme Register - Department of Health (UK)
Government
Government
The Department of Health
Richmond House
79 Whitehall
London
SW1A 2NL
United Kingdom
Website | http://www.doh.gov.uk |
---|
Funders
Funder type
Government
NHS Cardiovascular Disease and Stroke National Research and Development Programme (UK)
No information available
Results and Publications
Intention to publish date | |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Not provided at time of registration |
Publication and dissemination plan | Not provided at time of registration |
IPD sharing plan |
Study outputs
Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
---|---|---|---|---|---|
Results article | Results | 01/07/2004 | Yes | No |